# Title
Serdar Balcı

![](img%5CHallmarks-of-Cancer-10.jpg)

# Hallmarks of Cancer-1

# Serdar BALCI, MD

![](img%5CHallmarks-of-Cancer-11.jpg)

![](img%5CHallmarks-of-Cancer-12.png)

![](img%5CHallmarks-of-Cancer-13.png)

![](img%5CHallmarks-of-Cancer-14.png)

**Cell. 2000 Jan 7;100(1):57-70.**

![](img%5CHallmarks-of-Cancer-15.jpg)

![](img%5CHallmarks-of-Cancer-16.png)

<span style="color:#FFFFFF"> *Cell* </span>
<span style="color:#FFFFFF"> 2011 144, 646-674DOI:
(10.1016/j.cell.2011.02.013) </span>

**Cell. 2011 Mar 4;144(5):646-74**

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span>
*[Terms and Conditions](http://www.elsevier.com/termsandconditions)*

![](img%5CHallmarks-of-Cancer-17.jpg)

![](img%5CHallmarks-of-Cancer-18.png)

<span style="color:#FFFFFF"> *Cell* </span>
<span style="color:#FFFFFF"> 2011 144, 646-674DOI:
(10.1016/j.cell.2011.02.013) </span>

**Cell. 2011 Mar 4;144(5):646-74**

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span>
*[Terms and Conditions](http://www.elsevier.com/termsandconditions)*

![](img%5CHallmarks-of-Cancer-19.png)

**Cell. 2000 Jan 7;100(1):57-70.**

![](img%5CHallmarks-of-Cancer-110.jpg)

![](img%5CHallmarks-of-Cancer-111.png)

<span style="color:#FFFFFF"> *Cell* </span>
<span style="color:#FFFFFF"> 2011 144, 646-674DOI:
(10.1016/j.cell.2011.02.013) </span>

**Cell. 2011 Mar 4;144(5):646-74**

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span>
*[Terms and Conditions](http://www.elsevier.com/termsandconditions)*

![](img%5CHallmarks-of-Cancer-112.png)

**Cell. 2000 Jan 7;100(1):57-70.**

![](img%5CHallmarks-of-Cancer-113.jpg)

![](img%5CHallmarks-of-Cancer-114.png)

<span style="color:#FFFFFF"> *Cell* </span>
<span style="color:#FFFFFF"> 2011 144, 646-674DOI:
(10.1016/j.cell.2011.02.013) </span>

**Cell. 2011 Mar 4;144(5):646-74**

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span>
*[Terms and Conditions](http://www.elsevier.com/termsandconditions)*

![](img%5CHallmarks-of-Cancer-115.png)

**Cell. 2000 Jan 7;100(1):57-70.**

![](img%5CHallmarks-of-Cancer-116.jpg)

![](img%5CHallmarks-of-Cancer-117.png)

<span style="color:#FFFFFF"> *Cell* </span>
<span style="color:#FFFFFF"> 2011 144, 646-674DOI:
(10.1016/j.cell.2011.02.013) </span>

**Cell. 2011 Mar 4;144(5):646-74**

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span>
*[Terms and Conditions](http://www.elsevier.com/termsandconditions)*

![](img%5CHallmarks-of-Cancer-118.jpg)

![](img%5CHallmarks-of-Cancer-119.png)

<span style="color:#FFFFFF"> *Cell* </span>
<span style="color:#FFFFFF"> 2011 144, 646-674DOI:
(10.1016/j.cell.2011.02.013) </span>

**Cell. 2011 Mar 4;144(5):646-74**

<span style="color:#FFFFFF">Copyright © 2011 Elsevier Inc.</span>
*[Terms and Conditions](http://www.elsevier.com/termsandconditions)*

# 

**http://www.cellsignal.com/common/content/content.jsp?id=science-pathways**

![](img%5CHallmarks-of-Cancer-120.png)

**Robbins Basic Pathology**

# Hallmarks of Cancer

**Self-sufficiency in growth signals**

**Insensitivity to growth inhibitory signals**

**Evasion of cell death**

**Limitless replicative potential**

**Development of sustained angiogenesis**

**Ability to invade and metastasize**

**Genomic instability**

**Tumor-promoting inflammation**

![](img%5CHallmarks-of-Cancer-121.jpg)

# SELF-SUFFICIENCY IN GROWTH SIGNALS

# Self-Sufficiency in Growth Signals

- **Physiologic Growth**
  - **The binding of a growth factor to its specific receptor on the
    cell membrane**
  - **Transient and limited activation of the growth factor receptor,
    which in turn activates several signal-transducing proteins on the
    inner leaflet of the plasma membrane**
  - **Transmission of the transduced signal across the cytosol to the
    nucleus by second messengers or a cascade of signal transduction
    molecules**
  - **Induction and activation of nuclear regulatory factors that
    initiate and regulate DNA transcription**
  - **Entry and progression of the cell into the cell cycle, resulting
    ultimately in cell division**

![](img%5CHallmarks-of-Cancer-122.png)

![](img%5CHallmarks-of-Cancer-123.jpg)

![](img%5CHallmarks-of-Cancer-124.png)

![](img%5CHallmarks-of-Cancer-125.png)

![](img%5CHallmarks-of-Cancer-126.png)

![](img%5CHallmarks-of-Cancer-127.jpg)

![](img%5CHallmarks-of-Cancer-128.png)

![](img%5CHallmarks-of-Cancer-129.png)

![](img%5CHallmarks-of-Cancer-130.png)

![](img%5CHallmarks-of-Cancer-131.png)

![](img%5CHallmarks-of-Cancer-132.png)

![](img%5CHallmarks-of-Cancer-133.jpg)

**Robbins Basic Pathology**

![](img%5CHallmarks-of-Cancer-134.png)

**Robbins Basic Pathology**

![](img%5CHallmarks-of-Cancer-135.png)

![](img%5CHallmarks-of-Cancer-136.png)

**Robbins Basic Pathology**

![](img%5CHallmarks-of-Cancer-137.png)

**Robbins Basic Pathology**

# Growth Factors

- **Cancer cells synthesize the same growth factors to which they are
  responsive**
- **Glioblastomas**
  - **secrete platelet-derived growth factor (PDGF)**
  - **express the PDGF receptor**
- **Sarcomas**
  - **Make transforming growth factor-α (TGF-α)**
  - **TGF-α receptor**
- **Interaction with stroma**
  - **Tumor cells send signals to activate normal cells in the
    supporting stroma**
  - **Then the stromal cells produce growth factors that promote tumor
    growth**

# Growth Factor Receptors andNon-Receptor Tyrosine Kinases

**Mutant receptor proteins:**

**Deliver continuous mitogenic signals to cells**

**Even in the absence of the growth factor in the environment**

- **Overexpression of growth factor receptors**
  - **Hyperresponsive to levels of the growth factor that would not
    normally trigger proliferation**
- **ERBB1 (EGF receptor)**
  - **Overexpressed in 80% of squamous cell carcinomas of the lung**
  - **50% or more of glioblastomas**
  - **80% to 100% of epithelial tumors of the head and neck**
- **HER2/NEU (ERBB2)**
  - **Amplified in 25% to 30% of breast cancers**
  - **Adenocarcinomas of the lung, ovary, and salivary glands**
  - **Sensitive to the mitogenic effects of small amounts of growth
    factors**
  - **A high level of HER2/NEU protein in breast cancer cells is a poor
    prognosis**
  - **Anti-HER2/NEU antibodies used in breast cancer treatment**

# Downstream Signal-Transducing Proteins

- **They receive signal from receptors**
- **Carry signal to nucleus via**
  - **second messengers**
  - **cascade of phosphorylation**
- **If there is an autonomy in these signals there is continuous signal
  to nucleus**
- **RAS**
- **ABL**

# RAS protein

- **Most commonly mutated proto-oncogene in human tumors**
- **30% of all tumors contain RAS mutation**
- **More common in colon and pancreas carcinoma**
- **G protein**
  - **Phosphorylation via GTP**

![](img%5CHallmarks-of-Cancer-138.png)

# RAS

- **Normally**
  - **active when bound to GTP**
  - **Deactivated by GTPase**
  - **GTPase-activating proteins (GAPs)**
- **When mutated**
  - \_\_ cannot dephosphorylate\_\_
  - **Remains active**

**Robbins Basic Pathology**

![](img%5CHallmarks-of-Cancer-139.png)

# GAPs

- **GTPase-activating protein**
- **Neurofibromin-1 (NF-1)**
  - **loss-of-function mutation**
  - **activation of RAS**
  - **Neurofibromatosis develops**

**Robbins Basic Pathology**

![](img%5CHallmarks-of-Cancer-140.png)

# RAF/ERK/MAP kinase pathway

**Active in 60% of melanomas**

**BRAF mutation seen in papillary thyroid carcinomas**

**Robbins Basic Pathology**

# ABL

- **Non-receptor-associated-tyrosine kinase**
- **Chronic Myelogenous Leukemia**
  - **ABL translocates from Chr9 to Chr22**
  - **Fuses with BCR**
  - **Continuous activation**
  - **Also activates RAS pathway**
- **Targeted therapy is present**
  - **BCR-ABL kinase inhibitor (Gleevec)**

![](img%5CHallmarks-of-Cancer-141.png)

**Robbins and Cotran’s Pathological Basis of Diseases**

# Nuclear Transcription Factors

- **MYC, MYB, JUN, FOS, and REL oncogenes**
  - **Regulate the expression of growth-promoting genes, such as
    cyclins**

# MYC

- **Activate growth-promoting genes cyclin-dependent kinases (CDKs)**
- **Inhibit CDK inhibitors (CDKIs)**
- **Upregulating genes that promote aerobic glycolysis (Warburg
  effect)**
- **İncreased utilization of glutamine**
- **Translocation**
  - **t(8;14) Burkitt lymphoma**
- **Amplification**
  - **Breast, colon, lung**
  - **Neuroblastomas, Small cell cancers of lung (NMYC, LMYC)**

![](img%5CHallmarks-of-Cancer-142.png)

**Robbins and Cotran’s Pathological Basis of Diseases**

![](img%5CHallmarks-of-Cancer-143.png)

**Robbins and Cotran’s Pathological Basis of Diseases**

![](img%5CHallmarks-of-Cancer-144.png)

**Robbins and Cotran’s Pathological Basis of Diseases**

# Cyclins and Cyclin-Dependent Kinases

- **Checkpoints**
- **G0 → G1**
- **G1 → S**
  - **Restriction point**
  - **Rate-limiting step**

**Checkpoints to prevent proliferation of abnormal DNA**

![](img%5CHallmarks-of-Cancer-145.png)

**Inhibit**

**tumor growth**

**Activate tumor growth**

**Robbins Basic Pathology**

- **Increasing expression of cyclin D or CDK4 is common in neoplasia**
- **Cyclin D**
  - **breast, esophagus, liver, and a subset of lymphomas and plasma
    cell tumors**
- **CDK4**
  - **melanomas, sarcomas, and glioblastomas. **
- **CDKI**
  - **disabled by mutation or gene silencing in many human
    malignancies**
  - **Germline mutations of CDKN2A**
    - **25% of melanoma-prone**
  - **Somatically acquired deletion or inactivation of CDKN2A**

![](img%5CHallmarks-of-Cancer-146.png)

**Robbins Basic Pathology**

# Homework

**Rous sarcoma virus**

![](img%5CHallmarks-of-Cancer-147.jpg)

# INSENSITIVITY TO GROWTH INHIBITORY SIGNALS

**Tumor Supressor Genes**

# RB Gene: Governor of the Cell Cycle

- **13q14**
- **Retinoblastoma occurs as a similar disease both in sporadic and
  familial forms**
- **Familial disease is Autosomal Dominant trait**
- **RB gene homozygous loss in**
  - **breast cancer, small cell cancer of the lung, and bladder cancer**
- **Patients with retinoblastoma have increased risk of**
  - **Osteosarcoma and soft tissue sarcomas**

# Retinoblastoma

![](img%5CHallmarks-of-Cancer-148.jpg)

![](img%5CHallmarks-of-Cancer-149.jpg)

![](img%5CHallmarks-of-Cancer-150.jpg)

![](img%5CHallmarks-of-Cancer-151.jpg)

**Figure 2, from Pediatr Radiol. Jun 2012; 42(6): 738–749. PMCID:
PMC3530407**

![](img%5CHallmarks-of-Cancer-152.jpg)

**Figure 7.4b ** \_ The Biology of Cancer\_ \_\_ (© Garland Science
2007)\_\_

# Knudson two-hit hypothesis

![](img%5CHallmarks-of-Cancer-153.png)

**Robbins Basic Pathology**

![](img%5CHallmarks-of-Cancer-154.png)

**Robbins Basic Pathology**

# Does a cell become neoplastic when one Rb gene is mutated?

**No**

**Tumor Suppressor Genes require loss of function of both alleles to
become neoplastic**

**Which mechanisms cause loss of function in a gene?**

**Does a cell become neoplastic when one allele of proto-oncogene is
mutated?**

![](img%5CHallmarks-of-Cancer-155.png)

**Robbins Basic Pathology**

![](img%5CHallmarks-of-Cancer-156.png)

**cyclin E transcription**

**Robbins Basic Pathology**

![](img%5CHallmarks-of-Cancer-157.png)

**HPV E7 protein mimics here**

**cyclin E transcription**

**Robbins Basic Pathology**

![](img%5CHallmarks-of-Cancer-158.png)

![](img%5CHallmarks-of-Cancer-159.png)

![](img%5CHallmarks-of-Cancer-160.png)

# TP53 GeneGuardian of the Genome

- **Quiescence**
  - **Activation of temporary cell cycle arrest**
- **Senescence**
  - **Induction of permanent cell cycle arrest**
- **Apoptosis**
  - **Triggering of programmed cell death**

**Rb “senses” external signals, p53 monitors internal stress**

# p53 is activated by

**Anoxia**

**Inappropriate oncoprotein activity**

**Damage to the integrity of DNA**

**p53 is a DNA damage response protein**

# p53

- **Normally**
  - **p53 has a short half-life**
  - **After 20 minutes associates with MDM2 and destructed**
- **When cell is stressed**
  - **Protein kinases are activated**
    - **ATM (ataxia telangiectasia mutated)**
  - **Make post transcriptional modifications in p53**
  - **p53 is released from MDM2**
  - **p53 activity continues**
- **After repair**
  - **p53 induces MDM2 expression and p53 levels decrease to normal,
    cell cycle continues**

![](img%5CHallmarks-of-Cancer-161.png)

**Robbins Basic Pathology**

# p53-mediated cell cycle arrest

**p53 induces transcription of CDKI gene CDKN1A (p21)**

**p21 protein inhibits cyclin–CDK complexes**

**Prevents phosphorylation of Rb**

**Arresting cells in the G1 phase**

**Time to repair DNA damage**

# p53-induced senescence

**Involve global chromatin changes**

**Drastically and permanently alter gene expression**

**Permanent cell cycle arrest**

# p53-induced apoptosis

**Irreversible DNA damage**

**pro-apoptotic genes such as BAX and PUMA**

# p53

- **70% of human cancers have a biallelic loss in p53**
- **Others have defects in genes upstream or downstream of TP53**
- **p53 is inhibited by oncogenic DNA viruses**
  - **Hepatitis B virus**
  - **possibly EBV**

# Li-Fraumeni syndrome

**Inherit a mutant TP53 allele**

**25x more cancer by age 50**

**Sarcomas, breast cancer, leukemia, brain tumors, carcinomas of the
adrenal cortex**

**Younger age**

**Multiple primary tumors**

# Transforming Growth Factor-β Pathway

- **Potent inhibitor of proliferation**
- **TGF-β receptors I and II**
  - **Activate with dimerization**
- **Growth-suppressing activity**
  - **Transcriptional activation of CDKIs**
- **Repression of growth-promoting genes **
  - **MYC, CDK2, CDK4**
  - **Encoding cyclins A and E**
- **SMAD molecules**
  - **Transduce antiproliferative signals from the receptor to the
    nucleus**
- **TGF-β signaling activates epithelial-to-mesenchymal transition
  (EMT)**

![](img%5CHallmarks-of-Cancer-162.jpg)

**Figure 5.21 ** \_ The Biology of Cancer\_ \_\_ (© Garland Science
2007)\_\_

# Transforming Growth Factor-β Pathway Alterations

- **Mutations in**
  - **Type II TGF-β receptor**
    - **colon, stomach, and endometrium cancers**
  - **SMAD molecules**
    - **SMAD4 in pancreatic cancers**
- **100% of pancreatic cancers and 83% of colon cancers, at least one
  component of the TGF-β pathway is mutated**

![](img%5CHallmarks-of-Cancer-163.jpg)

**Figure 6.29d ** \_ The Biology of Cancer\_ \_\_ (© Garland Science
2007)\_\_

# Contact Inhibition

- **Nontransformed cells are grown in culture**
  - **Proliferate until confluent monolayers are generated**
  - **Cell–cell contacts formed in these monolayers suppress further
    cell proliferation**
- **In cancer cells**
  - **No contact inhibition**
  - **Proliferate and pile on top of one another**

![](img%5CHallmarks-of-Cancer-164.png)

**Figure 3.7 from The Biology Of Cancer (2007) - Weinberg**

![](img%5CHallmarks-of-Cancer-165.jpg)

**Figure 3.7a ** \_ The Biology of Cancer\_ \_\_ (© Garland Science
2007)\_\_

![](img%5CHallmarks-of-Cancer-166.jpg)

**Figure 3.12 ** \_ The Biology of Cancer\_ \_\_ (© Garland Science
2007)\_\_

![](img%5CHallmarks-of-Cancer-167.png)

**Figure 3.7 from The Biology Of Cancer (2007) - Weinberg**

# E-cadherin

- **E-cadherin mediates cell–cell contact in epithelial layers**
- **Tumor suppressor gene NF2 (neurofibromin-2, merlin), facilitates
  E-cadherin mediated contact inhibition**
- **Homozygous loss of NF2 → neural tumors**
  - **Neurofibromatosis**
- **E-cadherin is also regulated by APC (adenomatous polyposis coli
  gene)**

**No APC is present**

**β-Catenin is active independent of WNT status**

**WNT signal inhibits APC**

**β-Catenin enters nucleus**

**APC is active**

**β-Catenin is dectructed**

![](img%5CHallmarks-of-Cancer-168.png)

**Robbins Basic Pathology**

**No APC is present**

**β-Catenin is active independent of WNT status**

**WNT signal inhibits APC**

**β-Catenin enters nucleus**

**APC is active**

**β-Catenin is dectructed**

![](img%5CHallmarks-of-Cancer-169.png)

![](img%5CHallmarks-of-Cancer-170.png)

![](img%5CHallmarks-of-Cancer-171.png)

![](img%5CHallmarks-of-Cancer-172.png)

![](img%5CHallmarks-of-Cancer-173.png)

![](img%5CHallmarks-of-Cancer-174.png)

![](img%5CHallmarks-of-Cancer-175.png)

![](img%5CHallmarks-of-Cancer-176.jpg)

![](img%5CHallmarks-of-Cancer-177.png)

![](img%5CHallmarks-of-Cancer-178.png)

![](img%5CHallmarks-of-Cancer-179.png)

![](img%5CHallmarks-of-Cancer-180.png)

![](img%5CHallmarks-of-Cancer-181.png)

![](img%5CHallmarks-of-Cancer-182.png)

![](img%5CHallmarks-of-Cancer-183.png)

![](img%5CHallmarks-of-Cancer-184.png)

**Robbins Basic Pathology**

**β-Catenin is active in the nucleus**

![](img%5CHallmarks-of-Cancer-185.png)

**cyclin D1 and MYC transcribed for proliferation**

**TWIST and SLUG are expressed**

**They repress E-cadherin expression**

**Reduce contact inhibition**

**Robbins Basic Pathology**

# Adenomatous Polyposis Coli

- **APC is a tumor suppressor gene**
- **With one mutant allele**
  - **Hundreds to thousands of adenomatous polyps in the colon**
  - **By age 20s**
- **When other allele also mutated**
  - **Malignant transformation**
- **APC mutations are seen in 70% to 80% of sporadic colon cancers**
- **Colonic cancers with normal APC genes have activating mutations of
  β-catenin**
  - **Refractory to the degrading action of APC**

![](img%5CHallmarks-of-Cancer-186.jpg)

**Figure 7.22 ** \_ The Biology of Cancer\_ \_\_ (© Garland Science
2007)\_\_

![](img%5CHallmarks-of-Cancer-187.jpg)

**Figure 7.24a ** \_ The Biology of Cancer\_ \_\_ (© Garland Science
2007)\_\_
